Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

Johnson, Keith A.; Minoshima, Satoshi; Bohnen, Nicolaas I.; Donohoe, Kevin J.; Foster, Norman L.; Herscovitch, Peter; Karlawish, Jason H.; Rowe, Christopher C.; Carrillo, Maria C.; Hartley, Dean M.; Hedrick, Saima; Pappas, Virginia; Thies, William H.

doi:10.1016/j.jalz.2013.01.002

Cited by 603Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

Open access

Johnson, Keith A., Minoshima, Satoshi, Bohnen, Nicolaas I., Donohoe, Kevin J., Foster, Norman L., Herscovitch, Peter, Karlawish, Jason H., Rowe, Christopher C. +5 more·2013·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2013.01.002PMC PMC3733252

Open this paper in CoChat — free account Open PDF

Abstract

Positron emission tomography (PET) of brain amyloid b is a technology that is becoming more available, but its clinical utility in medical practice requires careful definition. To provide guidance to dementia care practitioners, patients, and caregivers, the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened the Amyloid Imaging Taskforce (AIT). The AIT considered a broad range of specific clinical scenarios in which amyloid PET could potentially be used appropriately. Peer-reviewed, published literature was searched to ascertain available evidence relevant to these scenarios, and the AIT developed a consensus of expert opinion. Although empirical evidence of impact on clinical outcomes is not yet available, a set of specific appropriate use criteria (AUC) were agreed on that define the types of patients and clinical circumstances in which amyloid PET could be used. Both appropriate and inappropriate uses were considered and formulated,and are reported and discussed here. Because both dementia care and amyloid PET technology are in active development, these AUC will require periodic reassessment. Future research directions are also outlined, including diagnostic utility and patient-centered outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2013.01.002

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical use of AD CSF and PET biomarkers are not currently indicated in most symptomatic individuals to include or exclude AD pathology.
“However, clinical use of AD CSF and PET biomarkers are not currently indicated in most symptomatic individuals to include or exclude AD pathology.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [10]
AD CSF and PET biomarkers are reserved for atypical, rapidly progressive, or early-onset syndromes, or when comprehensive evaluation is inconclusive.
“These tests are reserved for atypical, rapidly progressive, or early-onset syndromes, or when comprehensive evaluation is inconclusive.10,11”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [10]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Self-citation
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works
Self-citation
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864 · see citing works
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works
National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,992 · see citing works
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease
Albert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,630 · see citing works
Self-citation
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · see citing works
The Efficacy of Diagnostic Imaging
Fryback, D. G., & Thornbury, J. R. (1991) · Medical Decision Making · doi:10.1177/0272989x9101100203 · Cited by 1,294 · see citing works
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · see citing works
Self-citation
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · see citing works
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855 · see citing works
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833 · see citing works
Self-citation
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830 · see citing works
PET imaging of amyloid deposition in patients with mild cognitive impairment
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 725 · see citing works
Amyloid Deposition, Hypometabolism, and Longitudinal Cognitive Decline
Landau, S. M., Mintun, M., Joshi, A. D., Koeppe, R., Petersen, R. C., Aisen, P., Weiner, M., & Jagust, W. J. (2012) · Annals of Neurology · doi:10.1002/ana.23650 · Cited by 723 · see citing works
Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
Rowe, C. C., Ackerman, U., Browne, W. F., Mulligan, R. S., Pike, K. E., O'Keefe, G. J., Tochon‐Danguy, H., Chan, G., Berlangieri, S. U., Jones, G. R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671 · see citing works
Self-citation
18 F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
Vandenberghe, R. R., Laere, K. V., Ivanoiu, A., Salmon, É., Bastin, C., Triau, E., Hasselbalch, S. G., Law, I. G., Andersen, A., Kørner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 648 · see citing works
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608 · see citing works
Self-citation
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core
Jagust, W. J., Bandy, D., Chen, K., Foster, N. L., Landau, S. M., Mathis, C. A., Price, J. C., Reiman, E. M., Skovronsky, D., Koeppe, R. A., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.003 · Cited by 537 · see citing works
Self-citation
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
Jack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., et al. (2010) · Brain · doi:10.1093/brain/awq277 · Cited by 531 · see citing works
Conversion of amyloid positive and negative MCI to AD over 3 years
Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F., Någren, K., Bullock, R. M., Walker, Z., Kennedy, A. M., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b23564 · Cited by 522 · see citing works
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495 · see citing works
Self-citation
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476 · see citing works
Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods
Landau, S. M., Breault, C., Joshi, A. D., Pontecorvo, M. J., Mathis, C. A., Jagust, W. J., & Mintun, M. A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.109009 · Cited by 465 · see citing works
Imaging amyloid deposition in Lewy body diseases
Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. E., Mathis, C. A., Elmaleh, D. R., Shoup, T., Fischman, A. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000326146.60732.d6 · Cited by 443 · see citing works
Self-citation
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography
Edison, P., Rowe, C. C., Rinne, J. O., Ng, S., Ahmed, I., Kemppainen, N. M., Villemagne, V. L., O'Keefe, G. J., Någren, K., Chaudhuri, К. R., et al. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.127878 · Cited by 422 · see citing works
Self-citation
A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia
Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., Takuma, H., Kuwano, R., Imagawa, M., Ataka, S., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21321 · Cited by 414 · see citing works
Mixed Dementia
Langa, K. M., Foster, N. L., & Larson, E. B. (2004) · JAMA · doi:10.1001/jama.292.23.2901 · Cited by 392 · see citing works
Self-citation
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., Irizarry, M. C., Klunk, W. E., Mathis, C. A., DeKosky, S. T., et al. (2007) · PubMed · doi:10.1001/archneur.64.3.431 · Cited by 341 · see citing works
Self-citation
Amyloid imaging in mild cognitive impairment subtypes
Wolk, D. A., Price, J. C., Saxton, J. A., Snitz, B. E., James, J. A., López, O. L., Aizenstein, H. J., Cohen, A. D., Weissfeld, L. A., Mathis, C. A., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21598 · Cited by 339 · see citing works
ACCF Proposed Method for Evaluating the Appropriateness of Cardiovascular Imaging
Patel, M. R., Spertus, J. A., Brindis, R. G., Hendel, R. C., Douglas, P. S., Peterson, E. D., Wolk, M. J., Allen, J. M., & Raskin, I. E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.030 · Cited by 332 · see citing works
Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327 · see citing works
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD
Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst, A. J., Agarwal, N., Mormino, E. C., O'Neil, J. P., Janabi, M., Karydas, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823b9c5e · Cited by 318 · see citing works
Positron emission tomography imaging in dementia
HERHOLZ, K., CARTER, S. F., & JONES, M. (2007) · The British Journal of Radiology · doi:10.1259/bjr/97295129 · Cited by 287 · see citing works
Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging
Johnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.10.007 · Cited by 270 · see citing works
Self-citation
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB–PET longitudinal study
Villain, N., Chételat, G., Grassiot, B., Bourgeat, P., Jones, G., Ellis, K. A., Ames, D., Martins, R. N., Eustache, F., Salvado, O., et al. (2012) · Brain · doi:10.1093/brain/aws125 · Cited by 255 · see citing works
Self-citation
Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses
Ioannidis, J. P. A. (2011) · JAMA · doi:10.1001/jama.2011.713 · Cited by 253 · see citing works
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline
Doraiswamy, P. M., Sperling, R. A., Coleman, R. E., Johnson, K. A., Reiman, E. M., Davis, M. D., Grundman, M., Sabbagh, M. N., Sadowsky, C., Fleisher, A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661f74 · Cited by 228 · see citing works
Self-citation
Clinical Validation of 18 F-AZD4694, an Amyloid-β–Specific PET Radioligand
Cselényi, Z., Eriksdotter, M., Forsberg, A., Halldin, C., Julin, P., Schou, M., Johnström, P., Varnäs, K., Svensson, S., & Farde, L. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094029 · Cited by 225 · see citing works
Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease
Cairns, N. J., Ikonomović, M. D., Benzinger, T. L. S., Storandt, M., Fagan, A. M., Shah, A. R., Taylor‐Reinwald, L., Carter, D. R., Felton, A., Holtzman, D. M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.279 · Cited by 203 · see citing works
Assessment of β-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11–Labeled Pittsburgh Compound B
Leinonen, V. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.noc80013 · Cited by 199 · see citing works
Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia
Rowe, C. C., Pejoska, S., Mulligan, R. S., Jones, G. R., Chan, J. G., Svensson, S., Cselényi, Z., Masters, C. L., & Villemagne, V. L. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114785 · Cited by 193 · see citing works
Self-citation
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease
Villemagne, V. L., Mulligan, R. S., Pejoska, S., Ong, K. T., Jones, G. R., O'Keefe, G. J., Chan, J. G., Young, K., Tochon‐Danguy, H., Masters, C. L., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2088-x · Cited by 190 · see citing works
Self-citation
A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
Nordberg, A., Carter, S. F., Rinne, J., Drzezga, A., Brooks, D. J., Vandenberghe, R., Perani, D., Forsberg, A., Långström, B., Scheinin, N., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2237-2 · Cited by 186 · see citing works
Revised Criteria for Mild Cognitive Impairment May Compromise the Diagnosis of Alzheimer Disease Dementia
Morris, J. C. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3152 · Cited by 176 · see citing works
Dementia in hereditary cerebral hemorrhage with amyloidosis‐Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles
Natté, R., Maat‐Schieman, M. L. C., Haan, J., Bornebroek, M., Roos, R. A. C., & Van Duinen, S. G. (2001) · Annals of Neurology · doi:10.1002/ana.10040 · Cited by 166 · see citing works
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia
Burack, M. A., Hartlein, J. M., Flores, H., Taylor-Reinwald, L., Perlmutter, J. S., & Cairns, N. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c7da8e · Cited by 164 · see citing works
Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET
Ossenkoppele, R., Tolboom, N., Foster‐Dingley, J. C., Adriaanse, S. F., Boellaard, R., Yaqub, M. M., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2102-3 · Cited by 160 · see citing works
Cerebral amyloid angiopathy burden associated with leukoaraiosis: A positron emission tomography/magnetic resonance imaging study
Gurol, M. E., Viswanathan, A., Gidicsin, C. M., Hedden, T., Martínez‐Ramírez, S., Dumas, A. P., Vashkevich, A., Ayres, A. M., Auriel, E., van Etten, E. S., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23830 · Cited by 159 · see citing works
Self-citation
Association Between In Vivo Fluorine 18–Labeled Flutemetamol Amyloid Positron Emission Tomography Imaging and In Vivo Cerebral Cortical Histopathology
Wolk, D. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.153 · Cited by 156 · see citing works
Amyloid imaging of Lewy body‐associated disorders
Foster, E. R., Campbell, M. C., Burack, M. A., Hartlein, J. M., Flores, H. P., Cairns, N. J., Hershey, T. G., & Perlmutter, J. S. (2010) · Movement Disorders · doi:10.1002/mds.23393 · Cited by 147 · see citing works
Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials
Román, G. C., Wilkinson, D. G., Doody, R. S., Black, S. E., Salloway, S. P., & Schindler, R. J. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000088494 · Cited by 141 · see citing works
Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand
Juréus, A., Swahn, B., Sandell, J., Jeppsson, F., Johnson, A. E., Johnström, P., Neelissen, J. A. M., Sunnemark, D., Farde, L., & Svensson, S. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06812.x · Cited by 140 · see citing works
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease
Kadir, A., Marutle, A., Gonzalez, D., Schöll, M., Almkvist, O., Mousavi, M. T., Mustafiz, T., Darreh‐Shori, T., Nennesmo, I., & Nordberg, A. K. (2010) · Brain · doi:10.1093/brain/awq349 · Cited by 139 · see citing works
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia
Klunk, W. E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.006 · Cited by 128 · see citing works
Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography
Wolk, D. A., Zhang, Z., Boudhar, S., Clark, C. M., Pontecorvo, M. J., & Arnold, S. E. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302548 · Cited by 121 · see citing works
In Vivo Fibrillar β-Amyloid Detected Using [11C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults
Sojkova, J., Driscoll, I. F., Iacono, D., Zhou, Y., Codispoti, K.-E., Kraut, M. A., Ferrucci, L., Pletniková, O., Mathis, C. A., Klunk, W. E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.357 · Cited by 112 · see citing works
In vitro characterisation of BF227 binding to α-synuclein/Lewy bodies
Fodero‐Tavoletti, M. T., Mulligan, R. S., Okamura, N., Furumoto, S., Rowe, C. C., Kudo, Y., Masters, C. L., Cappai, R., Yanai, K., & Villemagne, V. L. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.042 · Cited by 104 · see citing works
Self-citation
PET Amyloid Ligand [11C]PIB Uptake and Cerebrospinal Fluid β-Amyloid in Mild Cognitive Impairment
Koivunen, J., Pirttilä, T., Kemppainen, N. M., Aalto, S., Herukka, S., Jauhianen, A. M., Hänninen, T., Hallikainen, M., Någren, K., Rinne, J. O., et al. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000163927 · Cited by 101 · see citing works
Detection of isolated cerebrovascular β‐amyloid with pittsburgh compound B
Greenberg, S. M., Grabowski, T. J., Gurol, M. E., Skehan, M. E., Nandigam, R. N. K., Becker, J. A., Garcı́a-Alloza, M., Prada, C. M., Frosch, M. P., Rosand, J. M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21528 · Cited by 96 · see citing works
Self-citation
Positron Emission Tomography Radiopharmaceuticals for Imaging Brain Beta-Amyloid
Vallabhajosula, S. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.02.005 · Cited by 90 · see citing works
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study
Ikonomovic, M., Abrahamson, E., Price, J., Hamilton, R., Mathis, C., Paljug, W. R., Debnath, M., Cohen, A., Mizukami, K., Dekosky, S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0943-2 · Cited by 90 · see citing works
Mild Cognitive Impairment or Questionable Dementia?
Petersen, R. C. (2000) · Archives of Neurology · doi:10.1001/archneur.57.5.643 · Cited by 88 · see citing works
[18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies
Rinne, J. O., Wong, D. F., Wolk, D. A., Leinonen, V., Arnold, S. E., Buckley, C. J., Smith, A. P. L., McLain, R. W., Sherwin, P. F., Farrar, G., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1051-z · Cited by 82 · see citing works
Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications
Laforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79 · see citing works
Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies
Kantarci, K., Yang, C., Schneider, J. A., Senjem, M. L., Reyes, D. A., Lowe, V. J., Barnes, L. L., Aggarwal, N. T., Bennett, D. A., Smith, G. E., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.007 · Cited by 70 · see citing works
11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease
Villemagne, V. L., McLean, C., Reardon, K. A., Boyd, A., Lewis, V., Klug, G. M., Jones, G. R., Baxendale, D., Masters, C. L., Rowe, C. C., et al. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.171496 · Cited by 67 · see citing works
Self-citation
Development and evaluation of compounds for imaging of β-amyloid plaque by means of positron emission tomography
Henriksen, G., Yousefi, B. H., Drzezga, A. E., et al. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0705-x · Cited by 64 · see citing works
Combination of 18 F-FDG PET and Cerebrospinal Fluid Biomarkers as a Better Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment Patients
Choo, I. H., Ni, R., Schöll, M., Wall, A. E., Almkvist, O., & Nordberg, A. K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121489 · Cited by 57 · see citing works
PET of Brain Prion Protein Amyloid in Gerstmann–Sträussler–Scheinker Disease
Kepe, V., Ghetti, B. F., Farlow, M. R., Bresjanac, M., Miller, K. J., Huang, S.-C., Wong, K. P., Murrell, J. R., Piccardo, P., Epperson, F., et al. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00306.x · Cited by 55 · see citing works
Severe Cerebral Amyloid Angiopathy Characterizes an Underestimated Variant of Vascular Dementia
Haglund, M., Sjöbeck, M., & Englund, E. M. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000079192 · Cited by 52 · see citing works
. Pittsburgh compound B binding in poststroke dementia.
Mok, V., Leung, E. Y. L., Chu, W., Chen, S., Wong, A., Xiong, Y., Lam, W., Ho, C. L., & Wong, K. S. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.12.014 · Cited by 52 · see citing works
Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography
Burke, J. F., Albin, R. L., Koeppe, R. A., Giordani, B., Kilbourn, M. R., Gilman, S., & Frey, K. A. (2011) · Brain · doi:10.1093/brain/awr089 · Cited by 48 · see citing works
Cerebral β‐amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator‐related hemorrhage
Ly, J. V., Rowe, C. C., Villemagne, V. L., Zavala, J. A., Ma, H., O'Keefe, G. J., Gong, S. J., Gunawan, R., Churilov, L. P., Saunder, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22072 · Cited by 34 · see citing works
Self-citation
The Impact of Experience with a Family Member with Alzheimer’s Disease on Views about the Disease across Five Countries
Blendon, R. J., Benson, J. M., Wikler, E., Weldon, K. J., Georges, J., Baumgart, M., & Kallmyer, B. A. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/903645 · Cited by 33 · see citing works
FDG-PET and molecular brain imaging in the movement disorders clinic
Bohnen, N. I., & Minoshima, S. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1be1 · Cited by 20 · see citing works
Self-citation
Validation of an 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for β-amyloid plaques
Wey, S., Weng, C.-C., Lin, K., et al. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.01.013 · Cited by 13 · see citing works

Flagged first, then by citations

Sorted by citations

Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · see citing works
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353 · see citing works
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912 · see citing works
Biomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159 · see citing works
Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia
Rabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674 · see citing works
Self-citation
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626 · see citing works
Self-citation
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623 · see citing works
“These tests are reserved for atypical, rapidly progressive, or early-onset syndromes, or when comprehensive evaluation is inconclusive.(10,11) In relatively typical cases, an individualized approach to history, examination, and selected laboratory”
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Hansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607 · see citing works
Self-citation
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526 · see citing works
Self-citation
Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density
Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4144 · Cited by 332 · see citing works
Multisite study of the relationships between antemortem [ 11 C]PIB‐PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology
La Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.001 · Cited by 317 · see citing works
Self-citation
Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions
Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293 · see citing works
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease
Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266 · see citing works
Self-citation
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Overk, C. R., & Masliah, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.015 · Cited by 242 · see citing works
Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale
Navitsky, M., Joshi, A. D., Kennedy, I., Klunk, W. E., Rowe, C. C., Wong, D. F., Pontecorvo, M. J., Mintun, M. A., & Devous, M. D. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.1353 · Cited by 229 · see citing works
Self-citation
Brain FDG PET and the Diagnosis of Dementia
Shivamurthy, V. K. N., Tahari, A. K., Marcus, C., & Subramaniam, R. M. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.13.12363 · Cited by 227 · see citing works
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226 · see citing works
Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing
Rowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24040 · Cited by 222 · see citing works
Self-citation
Designing the next-generation clinical care pathway for Alzheimer’s disease
Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., Chen, C., Cho, M., De Santi, S., Gao, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00269-x · Cited by 191 · see citing works
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
Amadoru, S., Doré, V., McLean, C. A., Hinton, F., Shepherd, C. E., Halliday, G. M., Leyton, C. E., Yates, P. A., Hodges, J. R., Masters, C. L., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00587-5 · Cited by 181 · see citing works
Self-citation
Anti-amyloid antibody therapies in Alzheimer's disease
Perneczky, R., Jessen, F., Grimmer, T., Levin, J., Flöel, A., Peters, O., & Froelich, L. (2023) · Brain · doi:10.1093/brain/awad005 · Cited by 182 · see citing works
Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
Bucci, M., Chiotis, K., Nordberg, A., & Initiative, F. T. A. D. N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01263-2 · Cited by 140 · see citing works
Mild to moderate Alzheimer dementia with insufficient neuropathological changes
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Blacker, D., Gómez‐Isla, T., Betensky, R. A., Growdon, J. H., Johnson, K. A., Frosch, M. P., Sperling, R. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24125 · Cited by 120 · see citing works
Self-citation
Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients
Initiative, F. T. A. D. N., Brendel, M., Pogarell, O., Xiong, G., Delker, A., Bartenstein, P., & Rominger, A. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2975-4 · Cited by 94 · see citing works
Recent Updates on Subcortical Ischemic Vascular Dementia
Roh, J. H., & Lee, J.-H. (2014) · Journal of Stroke · doi:10.5853/jos.2014.16.1.18 · Cited by 93 · see citing works
Phenotypic heterogeneity in dementia: a challenge for epidemiology and biomarker studies
Ryan, J., Fransquet, P., Wrigglesworth, J., & Lacaze, P. (2018) · Frontiers in Public Health · doi:10.3389/fpubh.2018.00181 · Cited by 91 · see citing works
Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment
Therriault, J., Pascoal, T. A., Benedet, A. L., Tissot, C., Savard, M., Chamoun, M., Lussier, F., Kang, M. S., Berzgin, G., Wang, T., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011416 · Cited by 91 · see citing works
Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration
Irwin, D. J., Lleó, A., Xie, S. X., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2017) · Annals of Neurology · doi:10.1002/ana.24996 · Cited by 67 · see citing works
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77 · see citing works
A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer’s Disease
Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68 · see citing works
Free water derived by multi‐shell diffusion MRI reflects tau/neuroinflammatory pathology in Alzheimer's disease
Nakaya, M., Sato, N., Matsuda, H., Maikusa, N., Shigemoto, Y., Sone, D., Yamao, T., Ogawa, M., Kimura, Y., Chiba, E., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12356 · Cited by 41 · see citing works
A Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics
Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092316 · Cited by 40 · see citing works
Atypical Alzheimer Disease Variants
Polsinelli, A. J., & Apostolova, L. G. (2022) · Continuum · doi:10.1212/con.0000000000001082 · Cited by 39 · see citing works
Use of amyloid PET across the spectrum of Alzheimer’s disease: clinical utility and associated ethical issues
Leuzy, A., Zimmer, E. R., Heurling, K., Rosa-Neto, P., & Gauthier, S. (2014) · Amyloid · doi:10.3109/13506129.2014.926267 · Cited by 31 · see citing works
Clinical applications of neuroimaging in patients with Alzheimer’s disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012
Soucy, J.-P., Bartha, R., Bocti, C., Borrie, M., Burhan, A. M., Laforce, R., & Rosa-Neto, P. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt199 · Cited by 25 · see citing works
Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid‐positive early Alzheimer's disease
Devanarayan, V., Charil, A., Horie, K., Doherty, T., Llano, D. A., Andreozzi, E., Sachdev, P., Ye, Y., Murali, L. K., Zhou, J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14411 · Cited by 19 · see citing works

Authors: Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., Hedrick, S., Pappas, V., & Thies, W. H.
Affiliations: Harvard University (US)
University of Washington (US)
University of Michigan (US)
Beth Israel Deaconess Medical Center (US)
University of Utah (US)
National Institutes of Health (US)
University of Pennsylvania (US)
Austin Hospital (AU)
Division of Medical and Scientific Relations Alzheimer's Association Chicago IL USA
Alzheimer's Association (US)
Society of Nuclear Medicine and Molecular Imaging (US)
ORCID: Johnson, Keith A.
Minoshima, Satoshi
Bohnen, Nicolaas I.
Donohoe, Kevin J.
Foster, Norman L.
Karlawish, Jason H.
Rowe, Christopher C.
Hartley, Dean M.
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2013-01
Volume: 9
Issue: 1
Pages: e-1
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2013.01.002
PMC: PMC3733252
OpenAlex: W2103346709
Cited by: 603
References: 79
Citations by year: 2026: 25 · 2025: 43 · 2024: 39 · 2023: 41 · 2022: 48 · 2021: 44 · 2020: 59 · 2019: 47 · 2018: 57 · 2017: 48 · 2016: 51 · 2015: 45 · 2014: 30 · 2013: 26
FWCI: 35.24
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 27 d)
Locations: Alzheimer s & Dementia (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Deep Blue (University of Michigan) (submittedVersion)
Funders: Alzheimer's Association
Society of Nuclear Medicine and Molecular Imaging
National Institute on Aging (R01AG027435, R01AG037497, P50AG005134, P01AG036694)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: amyloid PET, brain amyloid imaging
MeSH terms: Alzheimer Disease, Brain, Humans, Nuclear Medicine, Amyloid beta-Peptides, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks